特定人群室性心律失常风险评估进展及策略

doi:10.16150/j.1671-2870.2020.06.001

摘要/Abstract

中图分类号:

R541.7

陈信光, 张凤祥. 特定人群室性心律失常风险评估进展及策略[J]. 诊断学理论与实践, 2020, 19(06): 549-554.

图/表 1

参考文献 34

[1]	Hua W, Zhang LF, Wu YF, et al. Incidence of sudden cardiac death in China: analysis of 4 regional populations[J]. J Am Coll Cardiol, 2009, 54(12):1110-1118. doi: 10.1016/j.jacc.2009.06.016 URL
[2]	Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm So-ciety(APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population[J]. Europace, 2020, 22(8):1147-1148. doi: 10.1093/europace/euaa065 URL
[3]	Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology(AEPC)[J]. Europace, 2015, 17(11):1601-1687.
[4]	Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction[J]. Lancet, 1999, 353(9162):1390-1396. pmid: 10227219
[5]	Buxton AE, Fisher JD, Josephson ME, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT)[J]. Prog Cardiovasc Dis, 1993, 36(3):215-226. pmid: 8234775
[6]	Disertori M, Masè M, Rigoni M, et al. Heart rate turbulence is a powerful predictor of cardiac death and ventricular arrhythmias in postmyocardial infarction and heart failure patients: a systematic review and meta-analysis[J]. Circ Arrhythm Electrophysiol, 2016, 9(12): e004610.
[7]	Morin DP, Zacks ES, Mauer AC, et al. Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy[J]. Heart Rhythm, 2007, 4(7):904-912. doi: 10.1016/j.hrthm.2007.02.027 URL
[8]	Panza JA, Ellis AM, Al-Khalidi HR, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy[J]. N Engl J Med, 2019, 381(8):739-748. doi: 10.1056/NEJMoa1807365 URL
[9]	Disertori M, Rigoni M, Pace N, et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: a meta-analysis[J]. JACC Cardiovasc Imaging, 2016, 9(9):1046-1055. doi: S1936-878X(16)30409-0 pmid: 27450871
[10]	Yan AT, Shayne AJ, Brown KA, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality[J]. Circulation, 2006, 114(1):32-39. doi: 10.1161/CIRCULATIONAHA.106.613414 URL
[11]	Prystowsky EN, Nisam S. Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained Tachycardia Trial. Multicenter Automatic Defibrillator Implantation Trial[J]. Am J Cardiol, 2000, 86(11):1214-1215,A1215. pmid: 11090794
[12]	Biering-Sørensen T, Olsen FJ, Storm K, et al. Prognostic value of tissue Doppler imaging for predicting ventricular arrhythmias and cardiovascular mortality in ischaemic cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging, 2016, 17(7):722-731. doi: 10.1093/ehjci/jew066 pmid: 27084397
[13]	Bui AH, Cannon CP, Steg PG, et al. Relationship between early and late nonsustained ventricular tachycardia and cardiovascular death in patients with acute coronary syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial[J]. Circ Arrhythm Electrophysiol, 2016, 9(2):e002951.
[14]	Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart fai-lure[J]. N Engl J Med, 2016, 375(13):1221-1230. doi: 10.1056/NEJMoa1608029 URL
[15]	Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadoli-nium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis[J]. Circ Cardiovasc Imaging, 2014, 7(2):250-258. doi: 10.1161/CIRCIMAGING.113.001144 pmid: 24363358
[16]	Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias:the potential role of occult inflammation in arrhythmogenesis[J]. Heart Rhythm, 2015, 12(12):2488-2498. doi: 10.1016/j.hrthm.2015.08.014 URL
[17]	Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis[J]. Circ Arrhythm Electrophysiol, 2014, 7(3):407-413. doi: 10.1161/CIRCEP.113.000734 URL
[18]	Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance[J]. Circ Cardiovasc Imaging, 2016, 9(1):e003738.
[19]	Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis[J]. JACC Cardiovasc Imaging, 2013, 6(4):501-511. doi: 10.1016/j.jcmg.2012.10.021 pmid: 23498675
[20]	Aquaro GD, Perfetti M, Camastra G, et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study[J]. J Am Coll Cardiol, 2017, 70(16):1977-1987. doi: 10.1016/j.jacc.2017.08.044 URL
[21]	Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis[J]. J Am Coll Cardiol, 2014, 63(4):329-336. doi: 10.1016/j.jacc.2013.09.022 pmid: 24140661
[22]	van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes[J]. J Cardiovasc Electrophysiol, 2004, 15(7):759-770. doi: 10.1046/j.1540-8167.2004.03645.x URL
[23]	Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study[J]. Circulation, 2004, 109(16):1994-2000. pmid: 15051640
[24]	Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias[J]. Europace, 2014, 16(9):1257-1283. doi: 10.1093/europace/euu194 URL
[25]	Deac M, Alpendurada F, Fanaie F, et al. Prognostic va-lue of cardiovascular magnetic resonance in patients with suspected arrhythmogenic right ventricular cardiomyopathy[J]. Int J Cardiol, 2013, 168(4):3514-3521. doi: 10.1016/j.ijcard.2013.04.208 URL
[26]	Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy[J]. Circulation, 2017, 136(21):2068-2082. doi: 10.1161/CIRCULATIONAHA.117.030792 pmid: 29158215
[27]	Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013[J]. Heart Rhythm, 2013, 10(12):1932-1963. doi: 10.1016/j.hrthm.2013.05.014 URL
[28]	Anastasakis A, Papatheodorou E, Ritsatos K, et al. Sudden unexplained death in the young: epidemiology, aetio-logy and value of the clinically guided genetic screening[J]. Europace, 2018, 20(3):472-480. doi: 10.1093/europace/euw362 pmid: 28177452
[29]	Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy[J]. Eur Heart J, 2013, 34(40):3109-3116. doi: 10.1093/eurheartj/eht089 pmid: 23509228
[30]	Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia[J]. Circulation, 2009, 119(18):2426-2434. doi: 10.1161/CIRCULATIONAHA.108.829267 pmid: 19398665
[31]	Adler A, Rosso R, Chorin E, et al. Risk stratification in Brugada syndrome: clinical characteristics, electrocardiographic parameters, and auxiliary testing[J]. Heart Rhythm, 2016, 13(1):299-310. doi: 10.1016/j.hrthm.2015.08.038 URL
[32]	Sieira J, Conte G, Ciconte G, et al. A score model to predict risk of events in patients with Brugada Syndrome[J]. Eur Heart J, 2017, 38(22):1756-1763. doi: 10.1093/eurheartj/ehx119 pmid: 28379344
[33]	Yamagata K, Horie M, Aiba T, et al. Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome:a Japanese multicenter registry[J]. Circulation, 2017, 135(23):2255-2270. doi: 10.1161/CIRCULATIONAHA.117.027983 URL
[34]	Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada Syndrome: a pooled analysis[J]. Circulation, 2016, 133(7):622-630. doi: 10.1161/CIRCULATIONAHA.115.017885 pmid: 26797467

推荐级别	定义
可取	至少有1个随机对照临床研究,或有强有力的观察证据,或专家共识支持
可能可取	有小样本人群的随机对照临床研究支持,或使用不广泛
不可取	没有科学依据或者缺乏共识支持,不推荐使用

特定人群室性心律失常风险评估进展及策略

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 34

相关文章 6

编辑推荐

Metrics

本文评价

[1]	上海交通大学医学院附属瑞金医院肺小结节诊治和管理学科群专家组. 肺结节活检术风险管理瑞金专家共识[J]. 诊断学理论与实践, 2022, 21(01): 22-31.
[2]	刘彤, 王鑫. 心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558.
[3]	毛毅敏, 黄伸伸, 和雪改. 围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理[J]. 诊断学理论与实践, 2019, 18(1): 16-20.
[4]	林建华, 缪慧娴. 妊娠合并心脏病的分类诊断和妊娠风险评估[J]. 诊断学理论与实践, 2019, 18(06): 613-618.
[5]	俞庆宪, 吴云林,. 74例老年进展期胃癌营养状况评估与研究[J]. 诊断学理论与实践, 2014, 13(06): 620-621.
[6]	方丹红, 吴立群, 陆林, 楼盛, 顾刚, 沈永初, 陈秋静, 蒲里津, 沈卫峰,. 心脏钠离子通道α亚单位SCN5A基因多态性与特发性室性心律失常[J]. 诊断学理论与实践, 2007, 6(04): 353-357.